Summary:
- BioVaxys Technology Corp., a biotechnology company developing viral and oncology vaccine platforms, has strengthened its scientific team with the addition of Dr. David Berd as Vice President of Research and Development.
- Dr. Berd is a renowned immunologist and cancer vaccine expert, having previously served as Vice President of R&D at IMV Inc., a clinical-stage immuno-oncology company.
- His expertise in the development of cancer vaccines and immunotherapies will be valuable in advancing BioVaxys' pipeline, which includes a COVID-19 vaccine candidate and an ovarian cancer vaccine.